Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease
Jan 16, 2023 // Study Updates
The OHS contributed genotyping data from 7,500 consented participants to a groundbreaking global initiative to research the underlying biology of human disease and disease traits.
As the largest contributor to CanPath, the OHS is the only Canadian study to be included in the Global Biobank Meta-analysis Initiative (GBMI), which to date involves genetic data from 2.2 million participants that have been collated and harmonized across 23 large biobanks on four continents.
This Cell Genomics article explains how genome-wide association studies (GWASs) were used across 14 biobanks to look at genotypes and phenotypes for 14 common diseases and endpoints. The OHS provided data on health outcomes (endpoints) including asthma, primary open-angle glaucoma (POAG), idiopathic pulmonary fibrosis, uterine cancer, thyroid cancer, abdominal aortic aneurysm, venous thromboembolism (VTE), acute appendicitis, COPD, pneumonia, heart failure, cardiomyopathy (hypertrophic, dilated), and stroke.
Image source: Global Biobank Meta-analysis Initiative